Table 2 Clinical trials of ASCs in therapeutic angiogenesis for ischemic diseases

Ischemic cardiomyopathy

27 patients/36 months

I

Autologous ASCs

0.4 × 10⁶ cells/kg

0.8 × 10⁶ cells/kg

1.2 × 10⁶ cells/kg

Catheter-based transendocardial injection

NCT00426868

ST-elevation acute myocardial infarction

14 patients/6 months

I

Autologous ASCs

N/A

N/A

NCT00442806

Critical limb ischemia

13 patients/6 months

I/II

Autologous ASCs

100 × 10⁶ cells

Intramuscular injection

NCT01211028

Acute myocardial infarction

23 patients/36 months

II

ASCs

N/A

Intracoronary route

NCT01216995

Critical limb ischemia with diabetes

33 patients/12 months

I/II

Autologous ASCs

0.5 × 10⁶ cells/kg

1 × 10⁶ cells/kg

Intra-arterial administration through femoral artery

NCT01257776

Buerger’s disease

15 patients/24 weeks

I/II

Autologous ASCs

5 × 10⁶ cells/kg

Intramuscular infusion

NCT01302015

Lower limb ischemia

60 patients/12 months

I/II

Autologous ASCs

N/A

Coat the inside of a synthetic graft

NCT01305863

Chronic ischemic heart disease

60 patients/6 months

II

ASCs

N/A

N/A

NCT01449032

Chronic myocardial ischemia

28 patients/12 months

II

ASCs

0.4 × 10⁶ cells/kg (≤40 × 10⁶ cells)

Intramyocardial injection

NCT01556022

Critical limb ischemia

20 patients/48 weeks

I/II

Autologous ASCs

(100–300) × 10⁶ cells

Intramuscular injection

NCT01663376

Ischemic stroke

20 patients/24 months

II

Allogeneic ASCs

1 × 10⁶ cells/kg

Intravenous administration

NCT01678534

Ischemic heart failure

6 patients/6 months

N/A

Autologous ASCs

N/A

Intracoronary administration

NCT01709279

Critical limb ischemia

33 patients/12 months

I/II

Allogeneic ASCs

0.5 × 10⁶ cells/kg

1 × 10⁶ cells/kg

Administered intra-arterially

NCT01745744

Critical ischemia of the lower limbs

10 patients/1 year

I/II

Human ASCs

1 × 10⁶ cells/kg

Intramuscular injection

NCT01824069

Acute myocardial infarction

10 patients/6 months

I/II

Autologous ASCs

N/A

Implantation by a catheter delivery system and/or intravenously

NCT01974128

Chronic myocardial ischemia

3 patients/12 months

II

ASCs

0.8 × 10⁶ cells/kg (≤80 × 10⁶ cells)

Intramyocardial injection

NCT02052427

Diabetic with critical limb ischemia

48 patients/6 months

I/II

Autologous ASCs

0.5 × 10⁶ cells

Intra-arterial infusion

NCT02287974

Ischemic heart disease and heart failure

10 patients/6 months

I

Allogeneic ASCs

100 × 10⁶ cells

Intramyocardial injection

NCT02387723

Deep second-degree burn wound

5 patients/4 weeks

I

ALLO-ASC-DFU

N/A

External application

NCT02394873

Diabetic foot ulcer

5 patients/4 weeks

I

ALLO-ASC-DFU, a hydrogel sheet containing allogeneic ASCs

N/A

External application

NCT02394886

Heart failure

138 patients/6 months

II

Allogeneic ASCs

100 × 10⁶ cells

Intramyocardial injection

NCT02673164

Peripheral arterial disease

10 patients/6 months

I/II

Autologous ASCs

200 × 10⁶ cells

Intravenous injection; intra-adventitia (proximal to the lesion) injection; intramuscular injection

NCT02756884

Chronic nonhemorrhagic stroke

3 patients/6 months

I

Autologous ASCs

N/A

Transplantation into brain surrounding ischemic infarct

NCT02813512

Diabetic foot

240 patients/3 months

I

ASCs

N/A

N/A

NCT02831075

Stroke

400 patients/6 months

II/III

Allogeneic ASCs

1 × 10⁶ cells/kg

Intravenous infusion

NCT02849613

Critical lower limb ischemia

9 patients/24 weeks

I/II

ASCs

N/A

Intramuscular injection

NCT02864654

Diabetic foot ulcer

45 patients/20 weeks

II

Autologous ASCs

N/A

Local treatment

NCT02866565